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Abstract
The strong male predominance in Barrett’s esophagus (BE) and esophageal adenocarcinoma 
(EAC) remains inadequately explained, but sex hormones might be involved. We hypothesized 
that single nucleotide polymorphisms (SNPs) in the androgen pathway influence risk of 
developing BE and EAC. This genetic-epidemiological analysis included 14 studies from 
Australia, Europe and North America. Polymorphisms in 16 genes coding for the androgen 
pathway were analyzed using a gene-based approach: versatile gene-based test association study 
(VEGAS). This method evaluates associations between a trait and all SNPs within a specific gene 
rather than each SNP marker individually as in a conventional GWAS. The data were stratified for 
sex, body-mass index, waist-to-hip ratio, tobacco smoking and gastroesophageal reflux status. 
Included were data from 1,508 EAC patients, 2,383 BE patients, and 2,170 control participants. 
SNPs within the gene CYP17A1 were associated with risk of BE in the sexes combined (p=0.002) 
and in males (p=0.003), but not in females separately (p=0.3). This association was found in 
tobacco smokers (p=0.003), and in BE patients without reflux (p=0.004), but not in non-smokers 
(p=0.2) or those with reflux (p=0.036). SNPs within JMJD1C were associated with risk of EAC in 
females (p=0.001). However, none of these associations replicated in a subsequent sample. 
Fourteen other genes studied did not reach statistically significant levels of association with BE, 
EAC, or the combination of BE and EAC, after correcting for the number of genes included in the 
analysis. In conclusion, genetic variants in the androgen-related genes CYP17A1 and JMJD1C 
might be associated with risk of BE and EAC, respectively, but replication data with larger sample 
sizes are needed.
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Introduction
The reasons for the strong male predominance in the incidence of esophageal 
adenocarcinoma (EAC) and its precursor condition Barrett’s esophagus (BE) remain 
inadequately known.1,2 Understanding the basis for the male predominance in these 
conditions could bring new etiologic insights.1 Gastroesophageal reflux disease, obesity, and 
tobacco smoking are the main known risk factors,3,4 but they do not entirely explain the 
current male predominance in EAC or BE in western countries.5,6 Emerging evidence 
suggests that genetic factors may contribute to the etiology of BE and EAC,7–11 but these 
factors have not been investigated with respect to sex-specific differences. It has been 
hypothesized that sex hormones are involved in the male predominance.12 Most research 
addressing the influence of sex hormones has examined the female sex hormone estrogen, 
which has failed to provide robust evidence of strong associations.1 Another potentially 
relevant sex hormonal exposure is androgens, but the literature addressing the role of the 
male sex hormone androgen in the etiology of BE and EAC is limited. However, a recent 
case-control study found an increased risk of BE among participants with high levels of free 
testosterone and low levels of estrone sulfate.13 Androgen receptors are known to be 
expressed in EAC,14 and the risk of EAC seems to be decreased in prostate-cancer patients 
using anti-androgen therapy.15,16 However, to the best of our knowledge no study has 
evaluated single nucleotide polymorphisms (SNPs) in genes coding for the androgen 
pathway in relation to risk of BE or EAC. We conducted a large genetic-epidemiologic 
study to test whether SNPs in 16 genes encoding components of the androgen pathway are 
associated with the risk of developing BE or EAC.
Material and Methods
Study Design
We used summary data from a genome-wide association study (GWAS) conducted by the 
Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). The study was based on 
data from 14 cohort and case-control studies from Australia, Europe (England, Ireland and 
Sweden), and North America (Canada and the United States). Most of these studies had a 
population-based design. The data were used to study the associations between BE and EAC 
in relation to SNPs in 16 genes known to be involved in the androgen pathway: 1) Sex 
hormone-binding globulin (SHBG); 2) Steroid-5-Alpha-Reductase Alpha Polypeptide 1 (3-
Oxo-5 Alpha-Steroid) (SRD5A1); 3) Steroid 5 Alpha-Reductase 3 (SRD5A3); 4) 
Cytochrome P450, Family 17, Subfamily A, Polypeptide 1 (CYP17A1); 5) Cytochrome 
P450, Family 7, Subfamily A, Polypeptide 1 (CYP7A1); 6) Cytochrome P450, Family 1, 
Subfamily A, Polypeptide 1 (CYP1A1); 7) Cytochrome P450, Family 11, Subfamily B, 
Polypeptide 1 (CYP11B1); 8) Cytochrome P450, Family 11, Subfamily B, Polypeptide 2 
(CYP11B2); 9) Hydroxysteroid (11-Beta) Dehydrogenase 1 (HSD11B1); 10) Aldo-Keto 
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Reductase Family 1, Member D1 (AKR1D1); 11) Aldo-Keto Reductase Family 1, Member 
C4 (AKR1C4); 12) Cytochrome P450, Family 19, Subfamily A, Polypeptide 1 (CYP19A1); 
13) Jumonji Domain Containing 1C (JMJD1C); 14) Hydroxysteroid (11-Beta) 
Dehydrogenase 2 (HSD11B2); 15) UDP Glucuronosyltransferase 2 Family, Polypeptide B4 
(UGT2B4), and 16) 3-oxo-5-alpha-steroid 4-dehydrogenase 2 (SRD5A2).17 We could not 
include the Androgen Receptor (AR) and the Family With Sequence Similarity 9, Member B 
(FAM9B) genes, because no SNPs were genotyped within these genes, which are both on 
chromosome X. Thus, the final number of genes was 16.
Replication analyses of significant associations were performed in an independent set of 
data from the 1958 British Birth Cohort.18 More information about these participants can be 
found in the supplementary text.
Genotyping
Discovery Set—Genotyping of DNA from buffy coat samples was performed using the 
Illumina HumanOmni1-Quad platform. Annotations were based on version H of the 
Illumina product files and corresponded to the Genome Reference Consortium GRCh37 
release. The quality control (QC) has been published previously10. In brief, samples with 
call rates <95% that were an admixture of DNA from more than one patient (n=18) or had 
low DNA input and a weak signal (n=14) were removed from further analysis. The 
remaining 6,448 samples, including HapMap controls (n=68) and duplicate samples (n=67), 
underwent quality assurance (QA) and quality control (QC) as follows. Batch and plate 
effects were evaluated using intensity data and allelic frequency and checked for case-
control associations. No important batch or plate effects or case-control associations with 
experimental factors were found. We used heterozygosity, sex chromosome intensity data, 
identity by descent (IBD) analysis, visualization of B allele frequency (BAF), and log R 
ratio (LRR) plots to identify samples that had one or more of misannotated sex, unexpected 
relatedness, or were sample mixtures. Two mixed samples were discovered and removed 
from further analysis. In the case of misannotated sex or unexpected relatedness, if the 
source of the discrepancy could be identified, the samples were kept; otherwise they were 
removed (n=47) from further analysis. Finally, 6,061 samples, all with European ancestry, 
remained for analysis: 1,508 from EAC patients, 2,383 from BE patients, and 2,170 from 
control participants.
SNPs were excluded if they had missing call rates >5%, Hardy Weinberg equilibrium p-
values among controls ≤10e−4, discordances among any of the duplicate pairs, Mendelian 
errors, or minor allele frequencies <1%. After QA/QC, 802,272 SNPs remained and were 
used for the initial GWAS analysis from which we chose 389 SNPs located within the 16 
selected genes for use in the versatile gene-based test association study (VEGAS) analysis 
described below.
Replication Set—The DNA samples were genotyped using the Fluidigm TM high-
throughput platforms and Fluidigm 96.96 Dynamic Arrays according to the manufacturer's 
instructions and were read using the Fluidigm EP1 commercial system. Each array had a 
capacity for genotyping 96 samples against sets of 96 SNPs. DNA samples were plated in 
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sets of 96 samples and combined into 384-well arrays for genotyping, with the case and 
control samples mixed on each 384-well plate. Genotypes were automatically called using 
BioMark Genotyping Analysis software, but all cluster plots were also checked manually 
and adjusted as needed. The Barrett’s cases were identified at endoscopy with a confirmed 
histopathological diagnosis of intestinal metaplasia from the UK Barrett’s Oesophagus Gene 
Study as previously described.10 Control paricipants were ascertained from the Wellcome 
Trust Case Control Consortium 2 (WTCCC2) by frequency matching on age (five-year age 
bands) and sex to Barrett’s esophagus cases excluding individuals with a past history of 
cancer (excluding non-melanoma skin cancer). All recruited participants gave informed 
consent and the studies have been approved by the relevant institutional ethics review board.
The WTCCC2 study participants (control) were of European ancestry, as determined by 
projection onto the first two principal components of PCA of HapMap individuals, and were 
genotyped on a custom version of the Illumina Human1.2M-Duo array.19
Individuals with missing call rates >2% were removed from the analysis. SNPs were 
excluded based upon the same criteria as in the discovery set. After QC, 490,845 SNPs 
remained, from which we selected SNPs potentially associated with BE or EAC in the 
discovery set for use in the versatile gene-based test association study (VEGAS) analysis 
described below. The final replication set included 4613 participants: 851 BE patients, 977 
EAC patients), and 2785 control participants.
Association Analysis
BE and EAC were analyzed as separate outcomes and then were combined. The 
combination was considered appropriate since our previous study found a shared genetic 
background for BE and EAC.20 Case-control analyses were conducted with a log-additive 
logistic regression model where case status was regressed on each SNP genotype. The 
included covariates were sex, age and the first four principal component eigenvectors from 
principal component analysis (PCA). Eigenvectors were included as covariates to account 
for population stratification arising from ancestry. P-values for each SNP were calculated for 
each case type (EAC, BE and EAC+BE) and used as input for the VEGAS.
Stratified Analysis
To investigate potential gender differences, we stratified the analysis by sex. Previous 
studies have shown that gastroesophagael reflux disease, high body mass index (BMI) and 
tobacco smoking are risk factors for both BE and EAC.21–24 We therefore stratified 
participant data for gastroesophageal reflux disease (weekly reflux symptoms and no reflux 
symptoms), BMI (lean/normal BMI ≤25 kg/m2, overweight BMI >25 and ≤30 kg/m2, and 
obese BMI > 30 kg/m2), waist-to-hip ratio (WHR) (lean WHR ≤0.9 and obese WHR >0.9), 
and smoking status (non-smokers and ever smokers). Participants with missing data on any 
of these variables were excluded from the analysis. The stratified analyses were not further 
stratified on sex due to power issues.
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Versatile Gene-Based Test Association Study (VEGAS)
VEGAS is a gene-based approach that considers an association between a trait and all SNPs 
within a specific gene rather than each SNP marker individually as in a conventional 
GWAS.25 Even if the individual effect sizes at any given SNP are small, collectively all 
SNPs within a gene could still account for a substantial proportion of variation in risk. 
Therefore, studies of combined risk alleles might identify candidate genes influencing 
disease occurrence. By combining the effects of all SNPs in a gene into a statistic and 
correcting for linkage disequilibrium (LD), the gene-based procedure can assess combined 
effects between SNPs that would be missed in a standard GWAS. In this study, VEGAS was 
used to examine associations between androgen-pathway gene variants and risk of BE or 
EA.20 In brief, VEGAS explores associations on a per-gene basis using the p-values from all 
SNPs within a defined gene. An extended range of 10kb (upstream and downstream of the 
gene) for each gene was used. VEGAS corrects for LD as well as the number of SNPs 
within each gene. VEGAS takes account of LD between markers in a gene by using 
simulation based on the LD structure of a set of reference individuals, or, as in this study, 
using a custom set of individuals whose genotype information was available, i.e. the same 
individuals as analysed.25 A Bonferroni corrected p-value of 0.003 was considered 
statistically significant since the gene-based test included 16 genes (0.05/16=0.003). We also 
investigated if any single SNPs within each of the studied genes showed any independent 
effect on risk of BE, EAC or BE+EAC. For this approach, we used a Bonferroni corrected p-
value by dividing 0.05 by the number of SNPs within each gene.
Results
Study Participants
The age and sex distributions of the study participants in the discovery set (1508 EAC case 
patients, 2383 BE case patients, and 2170 control participants) were similar in the case 
groups and the control groups (Table 1). However, for the replication set (977 EAC case 
patients, 851 BE case patients, and 2785 control participants) the age and sex distribution 
differed between the case and control groups as detailed in Table 1.
Polymorphisms in the Androgen Pathway and risk of Barrett’s Esophagus and Esophageal 
Adenocarcinoma in the Discovery Set
In both genders combined, SNPs in CYP17A1 were statistically significantly associated with 
risk of BE (p=0.002; Table 2). Table 3 shows the results for the SNP with the lowest p-value 
in each gene. Only one single SNP within CYP17A1 was associated with BE after correction 
for multiple testing (rs4919686, p=0.001), which suggests that most of the association for 
this gene was due to this SNP. SNPs in CYP17A1 were associated with BE risk in males 
only (p = 0.003; Table 4), and an analysis stratified for tobacco smoking revealed an 
association between SNPs in CYP17A1 and risk of BE in smokers (p=0.003), but not in non-
smokers (Supplementary Table 2a). We also revealed an association between SNPs in 
CYP17A1 and BE risk in participants not suffering from reflux disease (p=0.004), but not in 
participants with reflux (Supplementary Table 2a). None of the other 15 genes reached 
statistically significant associations with BE, EAC or BE+EAC (Table 2). However, sex 
stratified analysis showed that JMJD1C was associated with risk of EAC in females 
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(p=0.001), but not in males (Table 4). None of the other stratified analyses revealed any 
significant associations with either of the phenotypes (Supplementary 2a–c).
Polymorphisms in JMJD1C and CYP17A1 and risk of Barrett’s Esophagus and Esophageal 
Adenocarcinoma in the Replication Set
We analyzed the replication set to examine the positive associations between SNPs in 
CYP17A1 and risk of BE and SNPs in JMJD1C and risk of EAC in females found in the 
discovery set. No statistically significant association was found for SNPs in CYP17A1 in 
males and females with BE (p=0.19) or for SNPs in CYP17A1 and BE in males (p=0.27; 
Supplementary Table 3). The association found between SNPs in JMJD1C and risk of EAC 
in females was not significant in the replication set (p=0.53; Supplementary Table 3).
Discussion
This study found an association between SNPs in the androgen-related genes CYP17A1 and 
risk of BE in males and both sex combined and JMJD1C and risk of EAC in females, but 
these associations were not found in the replication set. SNPs in the other 14 tested genes in 
the androgen pathway did not show any statistically significant influences on the risk of BE, 
EAC or BE+EAC.
Strengths of this study include the population-based design, the extensive data on genetic 
variants through the assessment of SNPs of relevant genes, and sample sizes that exceed 
those of most previous studies of BE and EAC. However, the limited number of female 
patients with BE or EAC makes it difficult to assess potential associations in females only or 
to ascertain potential differences in associations between the sexes. Additionally, statistical 
power decreased in sub-group analyses stratifying for covariates. Risk of type I errors is 
appreciable with large numbers of independent hypotheses, but Bonferroni correction is an 
established method to address such errors. Nevertheless, chance cannot be dismissed as a 
possible explanation for the potential associations found, particularly in light of the negative 
replication findings. Also, the lack of other associations might be due to type II errors. 
Moreover, no direct evidence is available to show that the gene variants addressed actually 
influence levels of androgen.
The lack of confirmation of the initial associations seen in the replication dataset should be 
interpreted cautiously. The statistical power was more limited in the replication set. 
Moreover, in each of the two genes, the set of genotyped SNPs between the datasets were 
not identical. Although both the discovery and replication set were of European ancestry, the 
discovery participants consisted mainly of individuals from the US and Australia 
(Supplementary Table 1), while the replication set was from only the UK. Also, the 
replication set had a higher proportion of females included as control participants compared 
to case patients, and the sex distribution was also different between case patients and control 
participants for the replication, which might influence the results.
To the best of our knowledge, no previous genetic study has addressed the specific 
hypothesis tested in the present study. However, some studies have found that anti-androgen 
therapy might decrease risk of EAC.14,15 The possible associations found in the present 
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study in combination with available epidemiologic evidence should prompt further research 
addressing the role of androgens in the etiology of BE and EAC and whether the male 
predominance might be explained by differences in androgen exposure. The present study 
was unable to examine risk associations with SNPs in AR, which could also be informative. 
The potential associations with SNPs in CYP17A1 might be interesting, since at least one 
functional SNP in this gene (rs743572) has been found to be of carcinogenic relevance in 
some tumors.26, 27 Interestingly, this SNP was nominally significant in our data (p=0.009 for 
BE and p=0.040 for BE+EAC). Moreover, the SNP with the lowest p-value in this study 
(rs4919686) has been associated with androgen-related disease occurrence.28 The CYP17A1 
association with BE, but not with EAC, might be explained by differences in effects of 
genes involved in the development or that CYP17A1 only has an importance in the 
development of BE, or a smaller effect on EAC than what we were able to pick up in this 
study. Regarding SNPs in the gene JMJD1C, GWAS-studies have found associations with 
testosterone levels29 and sex-hormone binding globulin levels,30 and such SNPs might also 
be of relevance for carcinogenesis.
The sex differences in associations are not likely to be explained by sex difference in the 
exposure to environmental risk factors, i.e. reflux, obesity and tobacco smoking, since the 
strengths of associations with EAC and BE are similar in men and women.5,6 Regarding the 
association with BMI, it has been argued that abdominal adiposity, the typical male fat 
distribution, may contribute to the male predominance of EAC, since abdominal obesity is 
associated with an elevated risk of EAC independent of BMI.22,31 However, a stratified 
analysis by BMI found no evidence of an increased male predominance among overweight 
individuals compared with lean, which argue against abdominal obesity as a factor 
contributing to the male predominance.32 The slope of the increase curve in the incidence of 
EAC is similar in both sexes, but the increase starts at a much later age in women.33 These 
factors taken together seem to argue in favor of sex hormonal influence.
In conclusion, although this large-scale genetic-epidemiological study does not provide 
strong overall support for polymorphisms in the androgen pathway being strongly associated 
with the risk of BE or EAC, it cannot dismiss the hypothesis that polymorphisms in 
CYP17A1 and JMJD1C might be associated with these diseases. However, these results 
need to be confirmed in independent studies with large sample size.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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The reasons for the strong male predominance in Barrett's esophagus and esophageal 
adenocarcinoma remain unknown, but sex hormonal influence has been suggested. This 
is the first genetic-epidemiologic study addressing genetic variants in the aetiology of 
Barrett's esophagus and esophageal adenocarcinoma. The results show that genetic 
variants in the androgen-related genes CYP17A1 and JMJD1C might be associated with 
risk of BE and EAC, respectively.
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